Boreo announced today that it has agreed to acquire Finnish medtech company Delfin Technologies. The target develops, produces and markets scientifically validated hand-held skin and edema measurement instruments and has a strong financial profile with c. 50% EBIT margins and EUR 2.5m sales in 2022. Delfin's profile differs from that of many other portfolio companies, which we expect to be reflected in the valuation. We find development of target profiles are interesting.
This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.